Compare Gilead Sciences, Inc. (GILD) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Wynn Resorts, Limited — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while Wynn Resorts, Limited trades at $75.15 (market cap $7.75B). The key difference: Gilead Sciences, Inc. is far larger — about 23.5× Wynn Resorts, Limited's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Wynn Resorts, Limited for 76 Days on average.
| GILD | WYNN | |
|---|---|---|
Market Cap | $182.40B | $7.75B |
Volume | 4,469,821 | 2,243,813 |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $133.09 |
52-Week Low | $117.18 | $74.97 |
Typical Hold Time | 111 Days | 76 Days |
Enterprise Value | $205.46B | $17.99B |
Dividend Yield | 2.23% | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 0.17% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings have mostly beaten expectations, though Q2 2026 saw a significant loss. The company maintains robust operating cash flow and has expanded access to its HIV prevention drug lenacapavir in Latin America, signaling growth potential in its core franchises.
The outlook is positive given analyst buy ratings and a $151.57 price target, but risks include negative net income margin and ROE in 2026, high debt levels, and reliance on pipeline success. The stock offers value if HIV and oncology advances materialize, yet investors face volatility from earnings inconsistencies and competitive pressures.
Wynn Resorts (WYNN) trades at $75.29, up 0.43% on the day, with a bearish technical signal from moving averages despite a neutral oscillator stance. The company reported a Q2 2026 earnings beat with EPS of $1.24 versus $0.992 expected, driven by Macau strength, though U.S. margins face pressure. Revenue for 2025 was $7.14B with a net income margin of 4.58%, while the balance sheet shows high leverage with total liabilities of $13.95B against negative shareholder equity. Recent news highlights institutional buying interest and a new $900 million senior notes offering.
The outlook is mixed: strong analyst consensus (64% buy ratings) and a $132.36 price target suggest upside, but high debt, rising capex for UAE projects, and volatile Macau performance pose significant risks. Investors should weigh growth potential against financial leverage and regional economic sensitivities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
